PROG, ADMP stocks jump after FDA approval, patent rights

October 18, 2021 05:12 PM PDT | By Sanjeeb Baruah
Follow us on Google News:


  • Progenity, Inc. (NASDAQ: PROG) secured four patents for ingestible technologies from the US Patent and Trademark Office (USPTO).

  • The PROG stock grew nearly 47% since the patent announcement on October 13.

  • Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) stock soared after FDA approval for its drug ZIMHI.

Stocks of Progenity, Inc. (NASDAQ: PROG) and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) jumped nearly 40% and over 8%, respectively, at the market close on Monday.

The PROG stock closed at US$2.99, up 39.72%, and the ADMP stock closed at US$1.23, up 8.85% at 4 pm ET.

Here is a look at the recent developments of the two companies.

Progenity, Inc.

The stock has been moving up since October 13, when the US Patent and Trademark Office (USPTO) granted four patents to the company for the ingestible technologies, which help administer drugs through the gastrointestinal tract. 

The stock raked in nearly 47% gain since that day. The San Diego, California-based company develops molecular testing products and precision medicine for various health problems. 

Also Read: Nine penny stocks with over 100% year-to-date return to explore

In the June quarter of 2021, the company posted revenue of US$463 thousand compared to no revenue in the year-ago period. The net loss was US$78.53 million compared to US$53.05 million in the June quarter of the prior year. 

Progenity’s market cap is US$372 million. The stock traded in the range of US$9.41 to US$0.66 in the last 52 weeks. On Oct 15, it closed at US$2.14 with a share volume of 71,829,450.

Also Read: From Netflix, Tesla to Intel - top stocks to watch this week

Trending healthcare stocks: Progenity, Inc. (NASDAQ: PROG) and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)

Source - Pixabay

Also Read: Former secretary of state Colin Powell dies aged 84

Adamis Pharmaceuticals Corporation

The Adamis stock saw high trading volume after the company announced obtaining approval from the US Food and Drug Administration (FDA) for its injection ZIMHI.

The biopharmaceutical company develops therapeutics for opioid overdose, inflammatory diseases, and allergy, and respiratory diseases. The naloxone injection is used to treat opioid overdose, including heroin, tramadol, fentanyl, morphine, etc. 

It’s another drug Tempol is currently under clinical trial. It is for treating COVID-19 patients.  

Also Read: Seven stocks to explore as demand for healthcare soars

For the fiscal year 2020, the company earned revenue of US$16.5 million compared to US$22.11 million in FY2019. The net loss was US$49.39 million for FY2020.  

The company has a current market capitalization of US$183 million. The highest and the lowest stock prices in the last 52 weeks were US$2.34 to US$0.38, respectively.

The stock closed at US$1.13 on Oct 15, 2021, with a share volume of 4,837,937.

Also Read: Top US retailers get ready to capitalize on holiday sales, boost stocks


Dow Jones US Pharmaceuticals Index (DJUSPR) generated a 7.31% return YTD but fell 0.39% in the last five days. On the other hand, the PROG stock grew around 35% over the past five days and lost nearly 43% YTD. In contrast, the ADMP stock rose 14% in the last five days and 125% YTD. Overall, the healthcare sector saw robust growth this year. However, investors must exercise caution before investing in stocks.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.